Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Baxter Acquires Hemophilia Assets from Archemix | Contract Pharma

What are you searching for?

Sign in
Breaking News

Baxter Acquires Hemophilia Assets from Archemix

Baxter has entered into a definitive agreement to acquire all of the hemophilia-related assets of Archemix, a privately-held biopharmaceutical company.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Baxter has entered into a definitive agreement to acquire all of the hemophilia-related assets of Archemix, a privately-held biopharmaceutical company. The two companies have also entered into an exclusive license agreement for certain related assets.

Archemix’s lead product ARC19499, is a synthetic, subcutaneously-administered hemophilia therapy currently in a Phase I trial. ARC19499 works by blocking Tissue Factor Pathway Inhibitor (TFPI) activity to increase and improve blood clotting, potentially reducing replacement factor therapy for patients with hemophilia A and B.

“Baxter is committed to optimizing hemophilia care and improving the lives of people living with hemophilia around the world,” said Hartmut Ehrlich, M.D., vice president, global research and development and medical affairs, for Baxter’s BioScience business. “This anti-TFPI program is an important addition to other Baxter hemophilia development programs focusing on longer-acting rFVIII and rFIX and non-intravenous therapies.”

Baxter expects to record a pre-tax in-process R&D charge of approximately $30 million in 4Q10 relating to an upfront payment associated with the transaction. Archemix will also be eligible to receive milestone-related payments of as much as $285 million. Subject to regulatory approvals and other conditions, the transaction is expected to close by year-end.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters